Prabhudas Lilladher has an accumulate call on GlaxoSmithKline Consumer Healthcare (GSK) with a target price of Rs ... is at 15 per cent discount our coverage universe. We value the stock at 35xDec19 and arrive at a target price of Rs 6,797.
It segments the market to understand the valuation of smaller aspects, takes stock of the potential of different regions ... Novartis, Merck & Co., GlaxoSmithKline, AstraZeneca and Novo Nordisk. On the basis of nutraceutical manufacturer …
while GSK chose to get rid of the well-known brands to focus on its core pharmaceutical business. According to the Managing Director, Suntory Beverage and Food Nigeria, Mr. Chinedum Okereke, takeover procedures with the Nigerian …
About PeptiDream Inc. PeptiDream Inc. is a public (Tokyo Stock Exchange First Section 4587 ... Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, …
Research Triangle Park, N.C. — Drug giants GlaxoSmithKline (NYSE ... Pfizer Chief Executive Officer Jeff Kindler in a joint statement issued to the London Stock Exchange. "With the strength of the companies' current HIV products, as well …
Could Lincoln's former Novartis plant, now majority owned by GlaxoSmithKline, be looking at another owner ... Some investors have called for Glaxo to split up to help boost a stock that has stagnated over the past year. The drugmaker is …
GlaxoSmithKline is one of the five most valuable companies listed on the stock market. Breaking it up, in the way Mr Woodford is proposing, would mean the company changing radically and is likely to involve a heated conflict between …
BBC2y
GlaxoSmithKline’s North American head Chris Viehbacher, who was in the running to replace Jean-Pierre Garnier as chief executive last year, is leaving the company. Mr Viehbacher, who held the posts of executive director and president, …
H1N1 swine flu vaccine maker GlaxoSmithKline released its fourth quarter profits ... with the majority of those sales coming in the first quarter of the year. The company’s stock has declined 2.5 per cent over the last 12 months.